Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway
Open accessThe DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease. During the past decade, novel pathogenic mechanisms of IPF have been elucidated that have shifted the concept of IPF from an inflammatory-driven to an epithelial-driven disease. Dysregulated repair responses induced by recurrent epithelial cell damage and excessive extracellular matrix accumulation result in pulmonary fibrosis. Although there is currently no curative therapy for IPF, two medications, pirfenidone and nintedanib, have been introduced based on understanding the pathogenesis of the disease. In this review, we discuss advances in understanding IPF pathogenesis, highlighting epithelial–mesenchymal transition (EMT), the ubiquitin-proteasome system, and endothelial cells. TGF-β is a central regulator involved in EMT and pulmonary fibrosis. HECT-, RING finger-, and U-box-type E3 ubiquitin ligases regulate TGF-β-Smad pathway-mediated EMT via the ubiquitin-proteasome pathway. p27 degradation mediated by the SCF-type E3 ligase, Skp2, contributes to the progression of pulmonary fibrosis by promotion of either mesenchymal fibroblast proliferation, EMT, or both. In addition to fibroblasts as key effector cells in myofibroblast differentiation and extracellular matrix deposition, endothelial cells also play a role in the processes of IPF. Endothelial cells can transform into myofibroblasts; therefore, endothelial–mesenchymal transition can be another source of myofibroblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“ND L02-s0201 (formerly BMS 986263) is a lipid nanoparticle containing siRNA which inhibits HSP47, which is a collagen specific chaperone that ensures proper collagen formation [190].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [190]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“CDK inhibitors (CKIs) such as p27Kip1 (p27) and p21Cip1 (p21), participate in regulation of the growth and differentiation of both epithelial and interstitial cells in various tissues [107].”
BackgroundSmad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539 · cited 3×
“Regarding interleukins, levels of the proinflammatory cytokine, IL-18, are elevated in serum, airway epithelium, and alveolar macrophages of patients with IPF [32].”
BackgroundInnate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
Cited by
Items 101–169 of 169
Biomarkers of Progressive Fibrosing Interstitial Lung Diseases
Валентиновна, Б. Е., & Yurkova, Y. G. (2023) · Innovative medicine of Kuban · doi:10.35401/2541-9897-2023-8-4-126-133 · Cited by 5
Sebastiani, M., Manfredi, A., Croci, S., Faverio, P., Cassone, G., Vacchi, C., Salvarani, C., & Luppi, F. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2376567 · Cited by 6
“TGFβ1-signaling has been the most studied and is a key driver of fibrosing ILD [93,94].”
Li, H., Wang, J., Li, Z., Wu, Z., Zhang, Y., Kong, L., Yang, Q., Wang, D., Shi, H., Shen, G., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39150 · Cited by 5
“Recent studies have explored the cytokine networks ’ role in mediating inflammation and pulmonary fibrosis, with TGF-β being the most extensively studied cytokine [4].”
Effect of FTY-720 on Pulmonary Fibrosis in Mice via the TGF-β1 Signaling Pathway and Autophagy
Jin, Y., Liu, W., Gao, G., Song, Y., Liu, H., Li, L., Zhou, J., Yan, G., & Cui, H. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.123 · Cited by 5
“TGF-β1 has been recognized as a master switch that regu- lates organ fibrosis (Rosenbloom et al., 2017; Hu et al., 2018), and is a pro-fibrotic cytokine in the pathogenesis of pulmonary fibrosis (Inui et al., 2021; Ye and Hu, 2021).”
Epithelial–Mesenchymal Transition in Osteosarcoma as a Key Driver of Pulmonary Metastasis
Luo, F., Ando, K., Takemura, Y., Park, T.-H., Yayama, T., & Imai, S. (2025) · Cancers · doi:10.3390/cancers17172922 · Cited by 4
“This enables them to form a complex with Smad4 (co-Smad) and translocate into the nucleus, where they regulate the transcription of EMT-related genes [9,19–22].”
Dong, L., Dong, W., Ren, Y., Xu, C., Wang, X., Sun, P., Meng, Y., Li, C., Li, G., Jiang, J., et al. (2025) · Engineering · doi:10.1016/j.eng.2025.10.017 · Cited by 5
Allicin reduces airway inflammation and remodeling in a murine asthmatic model
Shao, L., Liu, X., Liu, M., Zhao, Y., Chen, R., Wei, L., He, C., & Liu, Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152935 · Cited by 3
Zhao, C., Xiao, A., Chen, C., Mu, W., Li, W.-Y., & Chang, L. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102889 · Cited by 4
Gu, M.-Y., Ma, W., Ma, Z.-M., Ma, L., & Ding, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-94504-1 · Cited by 3
“By influencing proteasomal degradation mechanisms, it regulates cell proliferation and apoptosis processes 31 , and interacts with the immune system, thereby contributing to cancer development and progression 32 .”
Yao, Y., Lu, X., Zhao, L., Liao, H.-Y., Liu, Z., Zhao, H., Wang, H., Xu, D., & Tan, Z.-X. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117524 · Cited by 3
Chen, L., Chen, H., Chen, Z., Zhang, K., Zhang, H., Xu, J., & Chen, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-12046-y · Cited by 4
The molecular intersections of pulmonary fibrosis and lung cancer
Luo, B., Liu, X., Wang, S., Tong, Z., Han, Y., Tan, K., & Cao, P. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105042 · Cited by 2
TXNIP regulates the proliferation of scar fibroblasts through oxidative stress
Gong, W., Zhang, S., Zhang, R., Li, Y., & Zhai, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-03491-6 · Cited by 2
“Previous antifibrotic interventions, such as TGF-β inhibitors, have shown early efficacy but failed to sustain long-term benefits [33].”
Shionone ameliorates pulmonary fibrosis by activating mitophagy via PINK1-Parkin pathway
Su, Y., Fu, Q., Wu, X., Che, X., Jiang, Z., & Li, X. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117693 · Cited by 2
Percolation Forces in Lung Inflammation: Determining the Path to Emphysema or Fibrosis
Cantor, J. O. (2026) · Biomedicines · doi:10.3390/biomedicines14020281 · Cited by 2
“It also inhibits matrix degradation by reducing MMP expression and increasing tissue inhibitors of metalloproteinases [43].”
Recent updates on engineered nanomedicines for treatment of fibrosis
Ziada, A. R., Xin, C., & Elzoghby, A. O. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2628236 · Cited by 2
Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therapy
Yang, Y., Li, C., Xiong, W., Li, C., & Xiao, J. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102917 · Cited by 2
Li, S., Hou, Z., Gong, Y., Peng, J., Liang, H., Danmin, W., & Lin, L. (2023) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/9u1vzp · Cited by 2
“Previous studies have shown that the TGF-β signalling pathway is one of the main pathways regulating EndMT (14).”
BackgroundLuo, L., Yang, X., Zhao, H., Wang, L., Li, W., & Zhang, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-98842-y · Cited by 2
Lin, J., Wang, S., Li, J., Li, J., Wang, X., Wan, X., Gai, C., Chu, F., Gai, C., Li, Y., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120148 · Cited by 2
Yin, Y., Jia, N., Luo, H., Feng, X. L., He, X., Huang, J., & Wang, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1666698 · Cited by 3
Izosimova, V. E., Barmina, N. A., Zharikova, M. P., Alekseyev, O. Y., Ryzhkova, O. A., Сайфулин, М. Х., Popova, N. A., Andreyev, M. A., Гагарина, С. Г., Rysdauletova, R. M., et al. (2025) · Infectious Disorders - Drug Targets · doi:10.2174/0118715265329137250102103507 · Cited by 2
Han, M.-X., Cui, Y., Fang, Z., He, L. N., Wang, Y., Sima, M., Bi, Y., & Yue, D. (2025) · Biology · doi:10.3390/biology14020200 · Cited by 2
STAT3/NAV2 signaling promotes the progression of pulmonary fibrosis
Hu, D., Zhang, X., Wang, D., & Xie, W. (2025) · Molecular & Cellular Toxicology · doi:10.1007/s13273-025-00537-y · Cited by 1
Malik, R., Saeid, A. B., Allam, V. S. R. R., Shen, J., Paudel, K. R., Rubis, G. D., & Dua, K. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-025-01922-z · Cited by 1
“While current therapeutic strategies such as corticosteroids and bronchodilators provide symptomatic relief, they often fail to adequately address the underlying causes, leaving an unmet need for more targeted interventions [5–7].”
Pulito‐Cueto, V., Atienza‐Mateo, B., Batista-Liz, J., Nieto-Nieto, R., Vaquera-Illescas, C., Mora-Gil, M. S., Fernandez, D. I., Cuesta, V. M. M., Serrano-Combarro, A., Izquierdo‐Cuervo, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110722 · Cited by 1
Lemieszek, M. K., Chojnacki, M., Paśnik, I., Gawryś, W., Wilczyńska, A., Leśniowska, I., Anisiewicz, J., & Kiełbus, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411770 · Cited by 1
Wu, C.-S., Lai, D.-W., Chen, Y.-C., Yu, Y., Yang, L., & Fu, P.-K. (2026) · Respiratory Research · doi:10.1186/s12931-026-03596-4 · Cited by 1
A Lung-Targeted Carrier of Carbon Monoxide for Idiopathic Pulmonary Fibrosis Therapy
Guo, W., Huang, S., Zhang, J., Zhang, X., Yang, J., Bao, Y., & Zhang, J. (2026) · ACS Nano · doi:10.1021/acsnano.6c01762 · Cited by 1
Wu, J., Khaliq, H., Ke, Y., Ullah, Q., Sehgal, S. A., & Yi, X. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342991 · Cited by 2
“Endothelial cells, in turn, contribute to inflammation, angiogenesis, and the recruitment of immune cells, thus exacerbating fibrotic remodeling [17–20].”
Zhong, Y., Xiao, C., Liang, Y., Wang, P., Long, Y., Li, S., Song, N., Shang, W., Yang, W., & Zhang, X. (2026) · Natural Products and Bioprospecting · doi:10.1007/s13659-026-00593-4 · Cited by 1
“Pirfenidone and nint-edanib are representative drugs approved clinically for the treatment of PF, and they can prevent the decline of pulmonary function and slow down the disease progression [9].”
Miyauchi, A., Akashi, T., Yokota, S., Taquahashi, Y., Hirose, A., Hojo, M., Yoshida, H., Kurokawa, M., & Watanabe, W. (2023) · The Journal of Toxicological Sciences · doi:10.2131/jts.48.411 · Cited by 1
Upregulated SKP2 Empowers Epidermal Proliferation Through Downregulation of P27 Kip1
Tang, L., Zhang, B., Li, G., Qiu, X., Dai, Z., Liu, H., Zhu, Y., Feng, B., Su, Z., Han, W., et al. (2024) · Annals of Dermatology · doi:10.5021/ad.23.118 · Cited by 1
“6-8 , atherogenesis 9 , pulmonary fibrosis 10 , renal damage 11 .”
Wang, H., Liu, X., Huang, H., Tang, M., Li, J., Huang, T., & Wang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1510503 · Cited by 1
[FUT8 modulates galectin-3 expression to regulate TGF-β1-mediated fibrosis of lung fibroblasts].
Gao, W., Liu, D., Zhang, X., Feng, Q., & Liu, Y. (2022) · PubMed Central · doi:10.12122/j.issn.1673-4254.2022.08.08 · Cited by 2
Huang, S., Wu, X., Sun, Y., Xu, Z., & Zhang, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2706709/v1
Carvacrol Mitigates Bleomycin-Induced Experimental Pulmonary Fibrosis
Turgut, N. H., Gungor, H., Ekici, M., Karayığıt, M. Ö., & Kara, H. (2023) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093023050101
Effect of TAK242 on MCP-1 and TGF-β in COPD Rats
Deng, R., Mingyu, D., Xiaoyong, M., Chen, J., Zhang, H., Liu, M., Chen, J., & Chen, L. (2024) · Journal of Radiology and Oncology · doi:10.29328/journal.jro.1001060
“Among https://doi.org/10.29328/journal.jro.1001060 the many regulators of EMT, TGF-β is considered an important factor in pulmonary (cid:976)ibrosis [9].”
BackgroundInfluentialPulmonary fibrosis after a new coronavirus infection – versions and controversies: A review
Shchepikhin, E. I., Shmelev, E. I., & Эргешов, А. Э. (2024) · Terapevticheskii arkhiv · doi:10.26442/00403660.2024.03.202632
Cellular response in the pathogenesis of COVID-19
Sharma, L., Kim, J., & Cruz, C. S. D. (2024) · European Respiratory Society eBooks · doi:10.1183/2312508x.10019823
Wu, N., Xue, C., Yu, S., Wang, Y., Sun, D. F., & Ye, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-91423-z
“Inflammation and epithelial mesenchymal transition (EMT) play important roles in the pathogenesis of pulmonary fibrosis 26 .”
Aqil, M., Rahman, S. U., Aslam, M. Z., Ahmed, M. A. A., Ahmed, A., Javaid, S., & Haq, E. U. (2025) · Pakistan Journal of Medicine and Dentistry · doi:10.36283/ziun-pjmd14-2/059
Adult stem cells in regenerative medicine of respiratory system
Yaghoubi, A., Nazarnezhad, S., Asgharzadeh, F., Saeinasab, M., & Sefat, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34152-6.00008-1
Ginsenoside Re Inhibits Pulmonary Fibrosis by Regulating CX3CL1 / CX3CR1 Axis
Ling, H., Wen, Z., Xiao, H., Luo, T., & Deng, J. (2025) · Phytotherapy Research · doi:10.1002/ptr.70117 · Cited by 1
Ji, J., Zheng, S., Liu, Y., Xie, T., Zhu, X., Nie, Y., Shen, Y., & Han, X. (2023) · Figshare · doi:10.6084/m9.figshare.24165178
Ji, J., Zheng, S., Liu, Y., Xie, T., Zhu, X., Nie, Y., Shen, Y., & Han, X. (2023) · Figshare · doi:10.6084/m9.figshare.24165187
Ji, J., Zheng, S., Liu, Y., Xie, T., Zhu, X., Nie, Y., Shen, Y., & Han, X. (2023) · Figshare · doi:10.6084/m9.figshare.24165175
Kooistra, E. J., Dahm, K., van Herwaarden, A. E., Gerretsen, J., Nuesch-Germano, M., Mauer, K., Smeets, R. L., van der Velde, S., van den Berg, M. J. W., van der Hoeven, J. G., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23916723
Ji, J., Zheng, S., Liu, Y., Xie, T., Zhu, X., Nie, Y., Shen, Y., & Han, X. (2023) · Figshare · doi:10.6084/m9.figshare.24165184
Multi‐Omics Analysis Reveals the Molecular Subtypes and Confirmed the GREM1 as the Core Gene
Li, Z., Huang, H., Zhai, K., & Li, B. (2026) · The Journal of Gene Medicine · doi:10.1002/jgm.70067
Zhang, J., Xm, J., Sun, Y., Xia, R., & Chen, F. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.117736
Fu, C., Jing, X. B., Zhang, M., Cheng, Y., Yang, W., Wu, X., Chu, X., & Lu, X. (2026) · Biochemical Genetics · doi:10.1007/s10528-026-11325-1
“Previous studies have underscored the crucial involvement of TGF-β in the progression of IPF, which contributes to processes such as cell proliferation, differentiation, and matrix remodeling (Inui et al. 2021 ).”
WDR63 Promotes Pulmonary Fibrosis Through Facilitating K63 ‐Linked Ubiquitination of p53
Li, Y., Yang, Y., Zhang, Y., Shi, F., Wang, Y., Wen, H., Pan, X., Li, Z., Peng, M., Yang, J., et al. (2026) · Respirology · doi:10.1002/resp.70195
“IPF pathogenesis shares several features of aging, including dysregulated turnover, accumulated DNA damage, and dysregulated PTMs [34].”
Lin, Q., Zou, S., Lin, C., Lin, J., Wu, Y., Liu, R., & Lei, L. (2026) · Respiratory Research · doi:10.1186/s12931-026-03560-2
“…Skp2, an F-box protein component of the SCF ubiquitin ligase complex, is ubiquitously expressed across tissues (heart, kidney, liver, etc.) and orchestrates diverse processes including cell cycle progression and fibrosis by governing the turnover of key substrates (e.g., p27, FOXO1) [28, 49].”
Zhou, Y., Chen, X., Yang, J., Xue, S., Wang, Q., Xiao, H., Zhang, Y., & Niu, W. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.202503027
“This complex translocates to the cell nucleus, binds to the promoter regions of target genes, and promotes their transcription, thereby participating in the progression of PF [ 44, 45 ].”
Chen, W., Peng, J., Tang, X., Xiao, Y., Chen, Y., Tang, L., & Ouyang, S. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112445
Liu, Y., Wen, Z., Du, H., Hong, Y., Xu, Y., Wang, Z., & Hu, M. (2026) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2026.102235
Li, J., Chang, J., Chu, W., Jiang, Y., Sun, S., Ding, X., Zhang, L., & Shi, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062551
“KEGG pathway enrichment analysis showed that the calcium, TGF-β , IL-17, PI3K-Akt, and cAMP signaling pathways were highly enriched in BIPF mice on PID 21 (Figure 4A), among which TGF-β /Smad signaling is a crucial pathway in mediating the pathogenic process of BIPF [34,35].”
Identification of new levers to fight muscle atrophy : benefit of the hibernating brown bear model
Cussonneau, L. (2022) · theses.fr (ABES) · doi:10.70675/1a11a81bzf829z4ba2zba9az6f3f4841c773
Rôle des FGFs endocrines et leurs récepteurs au cours de la fibrose pulmonaire idiopathique
Ghanem, M. (2023) · theses.fr (ABES) · doi:10.70675/fd0d64f8zacf4z4856z9b1az66d4df37a332
Advances in pharmacotherapy for fibrotic interstitial lung disease
Feng, X., Deng, M., Miao, J., Zheng, Z., & Hou, G. (2026) · Medical Review · doi:10.1515/mr-2025-0086 · Cited by 1
“This molecular changes also confer resistance to apoptosis, collectively driving fi brosis [14, 18, 19].”
Decorin and IL-10 co-overexpression in BMDMSCs attenuates pulmonary fibrosis – an experimental study
Yue, Y., Lin, K., Fang, W.-F., Shao, P., Huang, C., Chen, Y., Wang, Y.-T., Yip, H., & Lee, M. S.-S. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000005530
Tan, G., Zhang, L., Wu, T., Liu, J., Wu, Y., Xiao, M., Wang, C., Pan, Z., Wang, S., Chen, C., et al. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2686511
“…fibroblast-to-myofibroblast differentiation, excessive collagen deposition, and extracellular matrix (ECM) remodeling via both canonical SMAD2/3 (Caja et al. 2018; Inui et al. 2021; Lee and Massagué 2022; Zhang et al. 2020) and noncanonical PI3K/Akt signaling pathways (Zhang et al. 2023; 2024b).”
Verma, S., Mehta, D., Kumar, S., Verma, Y. K., & Kalra, N. (2026) · PharmaNutrition · doi:10.1016/j.phanu.2026.100528
Rukonge, P. A., Kawuribi, V., Lu, Z., Oluwaseun, A. F., Sheng, Y., Yan, K., Zheng, Z., Liu, X., Chu, L., & Yu, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1889276
Li, L., Li, D., Bi, W., Sun, J., Bi, F., Tang, W., & Liu, S. (2026) · Toxicology in Vitro · doi:10.1016/j.tiv.2026.106295
β-carboline derivative Z86 alleviates pulmonary fibrosis via suppressing TGF-β/Smad signaling
Wang, Y., Zhang, S., Geng, R., Wang, R., Huang, Y., Xu, G., Kong, L., & Li, Y. (2026) · Natural Products and Bioprospecting · doi:10.1007/s13659-026-00628-w
Kobayashi, H. (2026) · American Journal of Reproductive Immunology · doi:10.1111/aji.70329
“Representative fibrotic disorders include pulmonary fibrosis [ 1, 2 ], liver fibrosis [ 3, 4 ], and renal fibrosis [ 5, 6 ].”
Cheng, J. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.16103332
Metadata
- Authors
- Inui, N., Sakai, S., & Kitagawa, M.
- Affiliations
- Hamamatsu University (JP)
- Corresponding author
- Inui, Naoki
- Kitagawa, Masatoshi
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-05
- Volume
- 22
- Issue
- 11
- Pages
- 6107
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8201174
- OpenAlex
- W3169709719
- Cited by
- 169
- References
- 119
- Citations by year
- 2026: 25 · 2025: 52 · 2024: 31 · 2023: 43 · 2022: 14 · 2021: 4
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (20K08539)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, TGF-beta signaling, ubiquitin-proteasome system, epithelial-mesenchymal transition, endothelial-to-mesenchymal transition, E3 ubiquitin ligase, p27 degradation, Skp2, myofibroblast differentiation, extracellular matrix deposition, interstitial lung disease, pirfenidone, nintedanib, fibroblast proliferation
- MeSH terms
- Humans, Pulmonary Fibrosis, Signal Transduction, Transforming Growth Factor beta, Proliferating Cell Nuclear Antigen, Ubiquitin, S-Phase Kinase-Associated Proteins, Proteasome Endopeptidase Complex, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.